Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

A standard protocol is described to study the antitumor activity and associated toxicity of IL-1α in a syngeneic mouse model of HNSCC.

Abstract

Cytokine therapy is a promising immunotherapeutic strategy that can produce robust antitumor immune responses in cancer patients. The proinflammatory cytokine interleukin-1 alpha (IL-1α) has been evaluated as an anticancer agent in several preclinical and clinical studies. However, dose-limiting toxicities, including flu-like symptoms and hypotension, have dampened the enthusiasm for this therapeutic strategy. Polyanhydride nanoparticle (NP)-based delivery of IL-1α would represent an effective approach in this context since this may allow for a slow and controlled release of IL-1α systemically while reducing toxic side effects. Here an analysis of the antitumor activity of IL-1α-loaded polyanhydride NPs in a head and neck squamous cell carcinoma (HNSCC) syngeneic mouse model is described. Murine oropharyngeal epithelial cells stably expressing HPV16 E6/E7 together with hRAS and luciferase (mEERL) cells were injected subcutaneously into the right flank of C57BL/6J mice. Once tumors reached 3-4 mm in any direction, a 1.5% IL-1a - loaded 20:80 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane:1,6-bis(p-carboxyphenoxy)hexane (CPTEG: CPH) nanoparticle (IL-1α-NP) formulation was administered to mice intraperitoneally. Tumor size and body weight were continuously measured until tumor size or weight loss reached euthanasia criteria. Blood samples were taken to evaluate antitumor immune responses by submandibular venipuncture, and inflammatory cytokines were measured through cytokine multiplex assays. Tumor and inguinal lymph nodes were resected and homogenized into a single-cell suspension to analyze various immune cells through multicolor flow cytometry. These standard methods will allow investigators to study the antitumor immune response and potential mechanism of immunostimulatory NPs and other immunotherapy agents for cancer treatment.

Introduction

One of the emerging areas of cancer immunotherapy is the use of inflammatory cytokines to activate patients' immune system against their tumor cells. Several proinflammatory cytokines (i.e., interferon-alpha (IFNα), interleukin-2 (IL-2), and interleukin-1 (IL-1)) can mount significant antitumor immunity, which has generated interest in exploring the antitumor properties as well as the safety of cytokine-based drugs. Interleukin-1 alpha (IL-1α) in particular, is a proinflammatory cytokine known as the master cytokine of inflammation1. Since the discovery of this cytokine in the late 1970s, it has been investigated as an anticancer ....

Protocol

All the in vivo procedures used in this study were approved by the Institutional Animal Care and UseCommittee (IACUC) of the University of Iowa.

1. Preparation and maintenance of HNSCC cell line

NOTE: In this study, the murine oropharyngeal epithelial cell line stably transformed with HPV E6 and E7 together with hRas and luciferase (mEERL) will be used. This cell line was developed from C57BL/6J mouse strain and was a gift from Dr. Paola D. Vermeer (Departmen.......

Representative Results

In this study, the antitumor activity of polyanhydride IL-1α in a syngeneic mouse model of HNSCC was investigated. Recombinant IL-1α (rIL-1α) significantly slowed mEERL tumor growth (Figure 1A), although weight loss was observed in the treated mice, which was restored after treatment withdrawal (Figure 1B). IL-1α-NPs did not induce a significant antitumor effect compared to saline or blank-NPs (Figure 1A) and was.......

Discussion

This protocol will allow any investigator to study the antitumor activity and some of the underlying mechanisms of immunomodulatory drugs in an in vivo tumor mouse model system. Here, a syngeneic subcutaneous tumor model was used, which has several advantages over orthotopic models, including its technically straightforward protocol, easy monitoring of tumor growth, less animal morbidity, and higher producibility. Subcutaneous tumor models can also be modified to a bilateral tumor model by injecting tumor cells .......

Acknowledgements

This work was supported in part by Merit Review Award #I01BX004829 from the United States (U.S.) Department of Veterans Affairs, Biomedical Laboratory Research and Development Service and supported by the Mezhir Award Program through the Holden Comprehensive Cancer Center at the University of Iowa.

....

Materials

NameCompanyCatalog NumberComments
Bio-Plex 200 SystemsBio-RadThe system was provided from the Flow Cytometry Facility University of IOWA Health Care
Bio-Plex Pro Mouse Cytokine 23-plex AssayBio-RadM60009RDPD
C57BL/6J MiceJakson Labs6644 to 6 weeks old
DMEM (Dulbecco's Modified Eagle Medium)Thermo Fisher Scientific11965092
DMEM/Hams F12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12)Thermo Fisher Scientific11320033
EGFMillipore SigmaSRP3196-500UG
Fetal Bovine SerumMillipore Sigma12103C-500ML
Gentamycin sulfate solutionIBI ScientificIB02030
gentleMACS DissociatorMiltenyi biotec
Hand-Held Magnetic Plate WasherThermo Fisher ScientificEPX-55555-000
HydrocortisoneMillipore SigmaH6909-10ML
InsulinMillipore SigmaI0516-5ML
Ketamine/xylazineInjectable anesthesia
MEERL cell lineMurine oropharyngeal epithelial cells stably expressing HPV16 E6/E7 together with hRAS and luciferase (mEERL) cells
Portable BalancesOhaus
Scienceware Digi-Max slide caliperMillipore SigmaZ503576-1EA
Sterile alcohol prep pad (70% isopropyl alcohol)CardinalCOV5110.PMP
Transferrin HumanMillipore SigmaT8158-100MG
Tri-iodothyroninMillipore SigmaT5516-1MG

References

  1. Dinarello, C. A., Simon, A., vander Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery. 11 (8), 633-652 (2012).
  2. de Mooij, C. E. M., Netea, M. G., vander Velden, W., Blijlevens, N. M. A.

Explore More Articles

In Vivo Antitumor ActivityPolyanhydride IL 1 NanoparticlesTumor ImplantationCytokine AnalysisImmune Cell PopulationsAntitumor EfficacyToxicity StudiesEERL CellsCell CultureSubcutaneous InjectionSubmandibular Blood Collection

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved